Contact:
4008465777
-
About Us
News & Events
-
09-05
Tonghua Dongbao announces NMPA acceptance of its NDA application for Etoricoxib Tablets
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") received the notice of acceptance (No. CYHS2302352, CYHS2302353, and CYHS2302354) from the National Medical Prod...
-
08-22
Tonghua Dongbao announces NMPA acceptance of its clinical trial application for oral small-molecule GLP-1 receptor agonist (THDBH110 Capsules)
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received ...
-
08-22
Tonghua Dongbao: Recovery growth in operational performance in H1 2023
On the evening of August 21, 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") released its semi-annual report for 2023. In H1 2023, the Company's revenue stood a...
-
06-01
Tonghua Dongbao: First subject enrolled in Phase I clinical trial on first Chinese-made dual-target inhibitor for gout (THDBH151 Tablets)
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") received the notice...
-
04-27
Tonghua Dongbao: Product sales continue to grow in Q1 2023
Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its Q1 2023 results on April 26. During the reporting period, the ...
-
04-22
For ten consecutive years | Tonghua Dongbao publishes 2022 CSR Report
On April 20, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2022 Corporate Social Responsibility (CSR) Report...